Effects of C5 complement inhibitor pexelizumab on outcome in high-risk coronary artery bypass grafting: Combined results from the PRIMO-CABG i and II trials

Journal of Thoracic and Cardiovascular Surgery

Volumn 142, Issue 1, 2011, Pages 89-98

  Smith, Peter K ^a   Shernan, Stanton K ^b   Chen, John C ^c   Carrier, Michel ^d   Verrier, Edward D ^e   Adams, Peter X ^f   Todaro, Thomas G ^g   Muhlbaier, Lawrence H ^a   Levy, Jerrold H ^h  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c UNIVERSITY OF HAWAII   (United States)

^d MONTREAL HEART INSTITUTE   (Canada)

^e UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^f ALEXION PHARMACEUTICALS   (United States)

^g PROCTER AND GAMBLE PHARMACEUTICALS   (United States)

^h EMORY UNIVERSITY HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEMENT COMPONENT C5 INHIBITOR; PEXELIZUMAB; PLACEBO; CREATINE KINASE MB;

ADULT; AGED; ANTHROPOMETRY; ARTICLE; CONTROLLED STUDY; CORONARY ARTERY BYPASS SURGERY; DEATH; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; EUROPE; FEMALE; FOLLOW UP; HEART ATRIUM FIBRILLATION; HEART INFARCTION; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; MORTALITY; NORTH AMERICA; PERIOPERATIVE PERIOD; POSTOPERATIVE INFECTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR; SURGICAL RISK; SURVIVAL RATE; TREATMENT OUTCOME; ATRIAL FIBRILLATION; CARDIOVASCULAR SURGERY; CONGESTIVE HEART FAILURE; CORONARY ARTERY BYPASS GRAFT; DRUG EFFECT; GENERAL CONDITION DETERIORATION; HEART MUSCLE CONDUCTION DISTURBANCE; HIGH RISK PATIENT; MIDDLE AGED; MULTICENTER STUDY; OUTCOME ASSESSMENT; PEROPERATIVE COMPLICATION; SURGICAL MORTALITY; VERY ELDERLY; WESTERN EUROPE;

ADULT; AGED; AGED, 80 AND OVER; ANTI-INFLAMMATORY AGENTS; ANTIBODIES, MONOCLONAL; CARDIOPULMONARY BYPASS; CHI-SQUARE DISTRIBUTION; COMPLEMENT C5; CORONARY ARTERY BYPASS; CORONARY ARTERY DISEASE; DOUBLE-BLIND METHOD; EUROPE; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; NORTH AMERICA; PROPORTIONAL HAZARDS MODELS; RISK ASSESSMENT; RISK FACTORS; SINGLE-CHAIN ANTIBODIES; TIME FACTORS; TREATMENT OUTCOME;

EID: 79959361476     PISSN: 00225223     EISSN: 1097685X     Source Type: Journal    
DOI: 10.1016/j.jtcvs.2010.08.035     Document Type: Article

References (19)

1. J.C. Fitch, S. Rollins, L. Matis, B. Alford, S. Aranki, and C.D. Collard Pharmacology and biological efficacy of a recombinant, humanized, single-chain antibody C5 complement inhibitor in patients undergoing coronary artery bypass graft surgery with cardiopulmonary bypass Circulation 100 1999 2499 2506 (Pubitemid 30005113)
2. H.J. Muller-Eberhard Molecular organization and function of the complement system Annu Rev Biochem 57 1988 321 347
3. A.P. Vakeva, A. Agah, S.A. Rollins, L.A. Matis, L. Li, and G.L. Stahl Myocardial infarction and apoptosis after myocardial ischemia and reperfusion Circulation 97 1998 2259 2267
4. J.W. Homeister, P. Satoh, and B.R. Bucchesi Effects of complement activation in the isolated heart: Role of the terminal complement components Circ Res 71 1992 303 319
5. T.C. Thomas, S.A. Rollins, R.P. Rother, M.A. Giannoni, S.L. Hartman, and E.A. Elliott Inhibition of complement activity by humanized anti-C5 antibody and single chain Fv Mol Immunol 33 1996 1389 1401 (Pubitemid 27196373)
6. E.D. Verrier, S.K. Shernan, K.M. Taylor, F. van de Werf, M.F. Newman, and J.C. Chen Terminal complement blockade with pexelizumab during coronary artery bypass graft surgery requiring cardiopulmonary bypass: A randomized trial JAMA 291 2004 2319 2327 (Pubitemid 38656298)
7. A.L. Shroyer, L.P. Coombs, E.D. Peterson, M.C. Eiken, E.R. DeLong, and A. Chen The Society of Thoracic Surgeons: 30-Day operative mortality and morbidity risk models Ann Thorac Surg 75 2003 1856 1865 (Pubitemid 36677229)
8. H.J. Geissler, P. Holzl, S. Marohl, F. Kuhn-Régnier, U. Mehlhorn, and M. Südkamp Risk stratification in heart surgery: Comparison of six score systems Eur J Cardiothorac Surg 17 2000 400 406 (Pubitemid 30204488)
9. K.A. Eagle, R.A. Guyton, R. Davidoff, G.A. Ewy, J. Fonger, and T.J. Gardner ACC/AHA Guidelines for coronary artery bypass graft surgery: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Revise the 1991 Guidelines for Coronary Artery Bypass Graft Surgery). American College of Cardiology/American Heart Association J Am Coll Cardiol 34 1999 1262 1347 (Pubitemid 29500568)
10. P.K. Smith, R.M. Califf, R.H. Tuttle, L.K. Shaw, K.L. Lee, and E.R. Delong Selection of surgical or percutaneous coronary intervention provides differential longevity benefit Ann Thorac Surg 82 2006 1420 1429 (Pubitemid 44429916)
11. A. Haverich, S.K. Shernan, J.H. Levy, J.C. Chen, M. Carrier, and K.M. Taylor Inhibition of complement activation by pexelizumab reduced death and myocardial infarction in higher risk cardiac surgical patients Ann Thorac Surg 82 2006 486 492 (Pubitemid 44096927)
12. P.K. Smith, M. Carrier, J.C. Chen, A. Haverich, J.H. Levy, and P. Menasché Effect of pexelizumab in coronary artery bypass graft surgery with extended aortic cross-clamp time Ann Thorac Surg 82 2006 781 788
13. C.B. Granger, K.W. Mahaffey, W.D. Weaver, P. Theroux, J.S. Hochman, and T.G. Filloon Pexelizumab, an anti-C5 complement antibody, as adjunctive therapy to primary percutaneous coronary intervention in acute myocardial infarction: The COMplement inhibition in Myocardial infarction treated with Angioplasty (COMMA) trial Circulation 108 2003 1184 1190 (Pubitemid 37099985)
14. Analysis of the Society of Thoracic Surgeons Adult Cardiac Database provided by the Society of Thoracic Surgeons and the Duke Clinical Research Institute, 2007.
15. P.W. Armstrong, C.B. Granger, P.X. Adams, C. Hamm, D. Holmes Jr., and W.W. O'Neill Pexelizumab for acute ST-elevation myocardial infarction in patients undergoing primary percutaneous coronary intervention: A randomized controlled trial JAMA 297 2007 43 51 (Pubitemid 46041725)
16. J.C. Mason Statins and their role in vascular protection Clin Sci (Lond) 105 2003 251 266 (Pubitemid 37088562)
17. R. Latini, S. Masson, R. Bertini, A.P. Maggioni, P. Ghezzi, and L. Calvillo Cardiac protection by pharmacological modulation of inflammation Expert Opin Investig Drugs 10 2001 1913 1924 (Pubitemid 33062215)
18. R.C. Landis, D.O. Haskard, and K.M. Taylor New anti-inflammatory and platelet-preserving effects of aprotinin Ann Thorac Surg 72 2001 S1808 S1813
19. C.D. Collard, S.C. Body, S.K. Shernan, S. Wang, D.T. Mangano Multicenter Study of Perioperative Ischemia (MCSPI) Research Group, Inc, et al Preoperative statin therapy is associated with reduced cardiac mortality after coronary artery bypass graft surgery J Thorac Cardiovasc Surg 132 2006 392 400 (Pubitemid 44092868)